The wait is over for Biogen Idec on its latest multiple sclerosis drug Plegridy (peginterferon beta-1a), with the Cambridge, Massachusetts company receiving word late on 15 August the FDA approved the medicine as a treatment for relapsing forms of the disease – the first and only pegylated beta interferon OK'd for the condition in the US.
The wait is over for Biogen Idec on its latest multiple sclerosis drug Plegridy (peginterferon beta-1a), with the Cambridge, Massachusetts company receiving word late on 15 August the FDA approved the medicine as a treatment for relapsing forms of the disease – the first and only pegylated beta interferon OK'd for the condition in the US.
Just last month, Plegridy gained approval in the European Union (scripintelligence.com, 25 July 2014).
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
